Business
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical needs provided a corporate update today and reported its financial results for the year ended December 31, 2024.
About this update from Brii Biosciences Limited
[{"type":"text","content":"Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure","length":158,"tagName":"p","attribs":{}},{"type":"text","content":"Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations","length":163,"tagName":"p","attribs":{}},{"type":"text","content":"4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30)","length":126,"tagName":"p","attribs":{}},{"type":"text","content":"Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"Actively Seeking Partnership Opportunities for Non-HBV Programs","length":63,"tagName":"p","attribs":{}},{"type":"text","content":"Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"DURHAM, N.C. and BEIJING, China, March 21, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical needs provided a corporate update today and reported its financial results for the year ended December 31, 2024.","length":395,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Brii Biosciences Limited)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Brii Biosciences Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":105,"url":"https://media.zenfs.com/en/prnewswire.com/a19981213a11806c724bc1d308aaae78"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V3nK_VGVGa.vonDXTWY9Ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a19981213a11806c724bc1d308aaae78","width":400,"height":105}},"href":"https://mma.prnewswire.com/media/1690538/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"In 2024, Brii Bio advanced its core hepatitis B virus (HBV) functional cure program, gaining valuable data from ongoing Phase 2 trials that support its goal of achieving higher functional cure r...